4-(4-Fluoro-phenyl)-2-methyl-pyridine | 844818-54-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(4-Fluoro-phenyl)-2-methyl-pyridine
• 英文别名: 4-(4-fluorophenyl)-2-methylpyridine
• CAS: 844818-54-8
• 化学式: C₁₂H₁₀FN
• 分子量: 187.217
• InChiKey: HFXSTBAHFYOVNK-UHFFFAOYSA-N

物化性质

• 沸点：
  263.7±25.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-Fluoro-phenyl)-2-methyl-pyridine 在 氯化亚砜 、 乙酸酐 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 17.0h， 生成 2-chloromethyl-4-(4-fluoro-phenyl)pyridine
  参考文献：
  名称：

  Inhibition of 1-Deoxy-d-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies

  摘要：

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

  DOI：

  10.1021/jm200363d
• 作为产物：
  描述：

  4-溴-2-甲基吡啶 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium chloride 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 4-(4-Fluoro-phenyl)-2-methyl-pyridine
  参考文献：
  名称：

  Preparation 2-Substituted-4-pyridylzinc Bromides via Direct Insertion of Active Zinc and Their Coupling Reactions

  摘要：

  DOI：

  10.5012/bkcs.2013.34.5.1575

文献信息

• 4-Aryl-pyridine-2-carboxyamide derivatives
  申请人：Jaeschke Georg

  公开号：US20070197553A1

  公开（公告）日：2007-08-23

  The present invention relates to novel pyridine-2-carboxyamide derivatives of formula (I) useful as metabotropic glutamate receptor antagonists: wherein Y, Z, R 1 , R 2 and R 3 are as defined in the specification herein.

  本发明涉及一种新型吡啶-2-羧酰胺衍生物，其化学式为(I)，可用作代谢型谷氨酸受体拮抗剂： 其中Y、Z、R1、R2和R3如本说明书中所定义。
• DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20110319381A1

  公开（公告）日：2011-12-29

  The invention relates to a compound of the general formula (I) in which R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, NR 8 R 9 group; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond or a C 1-8 -alkylene group; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl group or a trifluoromethyl group; R 4 is an optionally substituted 5-member heterocyclic compound; the compound being in the form of a base or acid addition salt. The invention also relates to the therapeutic use thereof.

  该发明涉及一般式（I）的化合物，其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基、NR8R9基团中的一种；m、n、o和p分别是等于0、1、2或3的整数；A是共价键或C1-8-烷基烯基团；R1是可选择取代的芳基或杂环芳基团；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；所述化合物为盐基或酸加合盐形式。该发明还涉及其治疗用途。
• [EN] NOVEL GAMMA-SECRETASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE L'ENZYME GAMMA-SECRETASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2005014553A1

  公开（公告）日：2005-02-17

  Compounds of Formula (I): inhibit the processing of APP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease.

  化合物的化学式（I）：抑制γ-分泌酶对APP的加工，因此对治疗或预防阿尔茨海默病有用。
• [EN] NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY<br/>[FR] NOUVEAUX INHIBITEURS D'HISTONE DÉACÉTYLASE ET LEUR UTILISATION EN THÉRAPIE
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2014072714A1

  公开（公告）日：2014-05-15

  A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.

  一种化合物的公式为：（I）或其药用可接受的盐，其中：L是一个5-成员含氮杂环，可选择地与苯融合；Y是一个5、6或7-成员含氮杂环，可选择地与苯融合；W是一个结合锌的基团。这些化合物是HDAC抑制剂，因此在治疗中具有潜在用途。
• Novel gamma-secretase inhibitors
  申请人：Bettati Michela

  公开号：US20060189666A1

  公开（公告）日：2006-08-24

  Compounds of Formula (I): inhibit the processing of APP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease.

  式(I)的化合物抑制γ-分泌酶对APP的加工，因此对于治疗或预防阿尔茨海默病有用。